Terumo to Increase Production Capacity for Alliance Business Pre-filled Syringes
Capital Investment of 7 Billion Yen in Terumo Yamaguchi D&D Corporation

July 9, 2018

TOKYO, JAPAN - July 9, 2018 - Terumo Corporation (TSE: 4543) today announced that it will construct an additional production facility for pre-filled syringes at the headquarters plant at Terumo Yamaguchi D&D Corporation, a Terumo subsidiary. The capital investment for the project will total approximately 7 billion yen. Construction is to begin in August 2018, and the facility is expected to go into operation in April 2021. This additional production facility will increase the production capacity at Terumo Yamaguchi D&D by approximately two-fold.

Yamaguchi City and Terumo Yamaguchi D&D Corporation held a signing ceremony today for the capital investment agreement.

Terumo Yamaguchi D&D Corporation operates a plant that produces Drug and Device products, which combine a medical devices and a drug in a single product. The plant is scheduled to formulate pharmaceutical products such as Humira® biosimilar (development no. FKB327, generic name: adalimumab), which is currently being reviewed for marketing approval in Europe.

Terumo Corporation will continue expanding its alliance business with pharmaceutical companies using the materials technologies and aseptic filling technology it gains from the manufacture of pre-filled syringes.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.